ANNUAL REPORT 2026 7 Board and Governance The year brought a natural evolution of your Board. Shortly before our Annual General Meeting in November 2025, we welcomed Chief Executive Officer James Bonnar to the Board of Directors, aligning his day-to-day stewardship of the Company with his governance responsibilities. Following the Annual General Meeting, we also marked the retirement of Dr Gisela Mautner, whom I thank warmly for her contribution and counsel. The Board remains committed to the highest standards of governance as the Company grows in complexity and reach. Looking Forward As we enter FY2027, our course is clear: to advance the PROTECT-MI trial to completion, to progress our IND towards lodgement, and to mature our preclinical programs towards the clinic. The PROTECT-MI trial remains on track for completion in CY2027, with top-line results anticipated in the second half of the calendar year. We do not underestimate the risks inherent in drug development, but we begin this next chapter with patients being dosed, an expanding pipeline of indications, and the capital and team to pursue it. To my fellow Non-executive Directors, thank you for your guidance and diligence. To our Managing Director and CEO James Bonnar and the entire Nyrada team, thank you for turning ambition into action. And to you, our CDI holders, thank you for your continued belief in what we are building. A year ago, I wrote that adventure awaited. This year, we set sail in earnest. Warm regards, John Moore Non-executive Chair Nyrada Inc.
RkJQdWJsaXNoZXIy MjE2NDg3